Pharmacyclics First to Announce Breakthrough Therapy Designation in ... The Herald | HeraldOnline.com A Phase II single-arm study of ibrutinib as a monotherapy in patients with MCL who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy, SPARK (MCL2001). - A Phase II single-arm study of ... |
